Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00423254

NCT00423254
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have an advanced solid tumour cancer that has not responded to previous treatments and has been confirmed by a tissue sample
  • Your cancer can be measured (for example, on a scan)
  • You are reasonably well and able to carry out daily activities (rated on a standard scale as 0, 1, or 2 — confirm with trial site)
  • Your bone marrow is producing enough blood cells, shown by blood test results meeting specific levels (confirm with trial site for exact numbers)
  • Your kidneys and liver are working well enough, shown by blood test results meeting specific levels (confirm with trial site for exact numbers)

Who may not be able to join:

  • You have cancer that has spread to your brain or spinal cord and is causing symptoms
  • You have any condition where your immune system attacks your own body (such as lupus or rheumatoid arthritis)
  • You have tested positive for HIV, hepatitis B, or hepatitis C
  • You have previously had a transplant using donated cells or an organ from another person
  • You have heart failure
  • You have cancer that has spread to the lymph nodes in your groin area, or you have had those lymph nodes surgically removed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Mannkind Corporation
Registry
clinicaltrials_gov
Start date
1 February 2007
Est. completion
1 September 2009

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov